Project will provide a valuable resource to the fast growing biological medicines sector through pharmacogenomics and analysis of new generations of vaccines and therapeutic proteins
Construction work begins on new state-of-the-art biological medicines analysis labs in Livingston, Scotland.
Scottish Enterprise CEO Jack Perry and Tepnel Life Sciences CEO Ben Matzilevich, perform ground-breaking ceremony at Tepnel's international facility due to come on stream in the second quarter of 2007.
The 40 week project, to be undertaken by Thermal Transfer, will see the realisation of a facility that will provide a valuable resource to the fast growing biological medicines sector through pharmacogenomics and analysis of new generations of vaccines and therapeutic proteins.
Scottish Enterprise CEO Jack Perry commented: "It is gratifying to see a UK-based company in a key industry for Scotland investing in the future by creating and expanding its business and adding jobs to the economy.
"This new facility will contribute to Scotland's economy and more specifically will open the door to the biopharmaceutical marketplace which is currently valued at £24 billion and has been growing at an impressive rate over the last five years."
